The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians-Reference-Cited by-同舟云学术

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Published:2020-09 Issue:9 Volume:31 Page:1115-1118
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Subbiah V.,Solit D.B.,Chan T.A.,Kurzrock R.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference17 articles.

1. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers;Goodman;Mol Cancer Ther,2017

2. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy;Khagi;Clin Cancer Res,2017

3. Phenotypic and genomic determinants of immunotherapy response associated with squamousness;Goodman;Cancer Immunol Res,2019

4. MHC-I genotype and tumor mutational burden predict response to immunotherapy;Goodman;Genome Med,2020

5. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort;Gene;2024-11

2. Precision oncology: current and future platforms for treatment selection;Trends in Cancer;2024-09

3. Tumour mutational burden: clinical utility, challenges and emerging improvements;Nature Reviews Clinical Oncology;2024-08-27

4. Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma;Frontiers in Immunology;2024-08-05

5. High-grade neuroendocrine head and neck cancer: Case series and review of the literature;Current Problems in Cancer;2024-08